Dr. Timos Papagatsias’ Post

This summer is flying - last month, I had the opportunity to attend Drug Information Association's annual conference - where they celebrated 60 years of collaboration on drug development and the future of therapy development. There are some key trends happening in clinical research that is evidence of the greater healthcare landscape: 1) topics that we have TALKED about for years are finally receiving federal regulation where companies are needing to take action on change 2) a shift is happening from: a healthcare industry that traditionally dictated to patients vs. now where we are seeing a demand from patients to be involved and influencing every step of the way from clinical trial design to value-based outcomes in clinical care 3) healthcare is trying to figure out how to use technology to solve its biggest problems...but if we move with haste without thoughtful change management, technology can become a burden for business and a roadblock for patients...AI has clear promise and benefits, but humans are still needed for intentional implementation. A couple things I thought were missing from the conference - a conversation about mental health and metal health studies, and women's health. Women are represented in just 40% of studies, even in diseases that are female-dominant. And when you track the #1 issue when ranked by burden - it's mental illness, also female-dominant. Track that against funding, and it falls to #5. Harvard's Study shows females underrepresented in key disease clinical trials: https://lnkd.in/gJp8KWkX Nature's Women's health research lacks funding - these charts show how: https://lnkd.in/gF-7cXMF We need to do better 💪

The Elusive Truth: What They Aren't Telling You About Your Health and Why It Matters unearths concealed elements of the healthcare industry that fundamentally affect patient care. The blog probes into undisclosed aspects such as influence of pharmaceutical companies, policy decisions and their impacts, suppression of negative clinical trial results, and concealed marketing strategies. It demands more transparency in the healthcare sector and encourages readers to question, challenge, and rewrite these hidden truths for better healthcare decisions.

The Elusive Truth: What They Aren't Telling You About Your Health and Why It Matters unearths concealed elements of the healthcare industry that fundamentally affect patient care. The blog probes into undisclosed aspects such as influence of pharmaceutical companies, policy decisions and their impacts, suppression of negative clinical trial results, and concealed marketing strategies. It demands more transparency in the healthcare sector and encourages readers to question, challenge, and rewrite these hidden truths for better healthcare decisions.

The Elusive Truth: What They Aren't Telling You About Your Health and Why It Matters unearths concealed elements of the healthcare industry that fundamentally affect patient care. The blog probes into undisclosed aspects such as influence of pharmaceutical companies, policy decisions and their impacts, suppression of negative clinical trial results, and concealed marketing strategies. It demands more transparency in the healthcare sector and encourages readers to question, challenge, and rewrite these hidden truths for better healthcare decisions.

When it comes to #pharmaceutical and #biotech companies and their #reputation with doctors, fighting for #patientaccess to new medicines will improve their reputation, according to a survey of 540 physicians. The study, published by WE Communications titled 'Reputation Rules: Unlocking Physician Prescribing Power', shows almost two in three Australian physicians believe fighting for patient access can improve the reputation of a company. "The research emphasises the importance of ensuring the extensive work the industry does in supporting and advocating for access is communicated to the prescribing community," WE Communications Australia Head of Health Emma Hussey told MedNews Aust/NZ. "HCPs want #transparency from industry and, in return, are willing to partner to support efforts towards better access for patients.” Full analysis in today's MedNews Aust/NZ (paywall). #corporatereputation #pharmareputation #fightforpatients #medicinesaccess #patientaccessgap

I look forward to connecting with our MedTech industry friends in the regulatory space - happening this week in Baltimore! Message me if you will be at the conference and would like to connect. #regulatory #reimbursement #partnership #medtechinnovation

Sara Zborovski and Ian Trimble provide an overview of Canada’s Proposed Pharmacare Act in this webinar (https://bit.ly/4eiQAdl), part of an exclusive Stikeman Elliott event that also featured Stephen Sampson and Andrew Retfalvi from Global Public Affairs. Find out what the new Pharmacare legislation could mean for Canadian business. #PharmacareAct #LifeSciences #HealthcareRegulation #CanadianLaw 

Are you prepared to meet the evidence needs of patients, providers, regulators, and payers? Check off the keys for a successful integrated evidence generation strategy with UBC’s Global Evidence Generation Checklist: https://hubs.li/Q02k4PDK0 #PatientsFirst #RWE #RealWorldEvidence #Pharma #DrugDevelopment

Revolutionize the way you connect and embrace a new age of streamlined engagement between healthcare professionals and Pharma with Golgi-CONNECT™ 🌐💡🤝

Efficient Medical Information and Call Center operations are crucial for compliance, pharmacovigilance, and stakeholder satisfaction in biopharma. Our latest video breaks down Best Practices' new study, which includes key insights from 22 industry leaders. Watch now to transform your Medical Info & Call Center operations! 👉 https://lnkd.in/dEMpiTfR #MedicalInformation #CallCenter #MedCallCenters #Biopharma #Pharma #MedicalAffairs #MedAffairs #Biotech #Salesforce #BestPracticesLLC